Human Vaccines & Immunotherapeutics最新文献

{"title":"Economic evaluations of vaccines against respiratory infections in adults in Southeast Asia: A systematic review.","authors":"Ba Khuong Cao, Rachmadianti Sukma Hanifa, Thi-Phuong-Lan Nguyen, Maarten J Postma, Jurjen van der Schans","doi":"10.1080/21645515.2025.2528409","DOIUrl":"10.1080/21645515.2025.2528409","url":null,"abstract":"<p><p>Respiratory infections significantly impact adult health in Southeast Asia, yet vaccine coverage remains low. This systematic review evaluated the economic evaluations of vaccines targeting respiratory infections in the region. A comprehensive search was conducted across several databases, including MEDLINE/PubMed, EMBASE, NHSEED, CINAHL, EconLit, Web of Science, Scopus, and Cochrane Library, up to April 24, 2024. Nineteen eligible studies were identified, focusing primarily on influenza (8 studies) and COVID-19 vaccines (7 studies), with fewer studies on pneumococcal (2 studies), varicella (1 study), and pertussis (1 study) vaccines. Overall, influenza, COVID-19 (boosters), and pneumococcal vaccines were found to be cost-effective or highly cost-effective compared to no-vaccine or no-booster scenarios. The only study on maternal pertussis vaccination found it not to be cost-effective. The most common parameters considered in sensitivity analyses were vaccine efficacy and discount rates. This review highlights the economic evaluations of influenza, COVID-19, and pneumococcal vaccines in Southeast Asia, providing essential evidence to guide vaccine policy. Future studies should address limitations in model selection, incorporate herd immunity, ensure the model validation (i.e. validity of cost and benefit measurements), and explore the cost-effectiveness of other vaccines across the region.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2528409"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12269661/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144643959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety, immunogenicity and pregnancy outcomes in mothers and infants after vaccination with an adenovirus-vector COVID-19 vaccine during pregnancy.","authors":"Gloria Aguilar, Gabriela Tapia-Calle, Cynthia Robinson, Benoit Baron, David Lowson, Bassem Maximos, Veronica V Rezelj, Anne Marit de Groot, Nicole Bet, Vitalija van Paassen, Mathieu Le Gars, Frank Struyf, Javier Ruiz-Guiñazú","doi":"10.1080/21645515.2025.2538340","DOIUrl":"10.1080/21645515.2025.2538340","url":null,"abstract":"<p><p>COVID-19 during pregnancy can be associated with adverse pregnancy and infant outcomes. We assessed the safety, reactogenicity, and immunogenicity of maternal vaccination with Ad26.COV2.S COVID-19 vaccine and monitored serum and breast milk antibody levels in mothers and infants until 6 months post-delivery. This open-label Phase 2 study enrolled previously COVID-19 vaccinated or COVID-19-vaccine-naive healthy pregnant women in trimester two or three (NCT04765384). All women received a single dose of Ad26.COV2.S. Mothers and infants were followed-up for safety until 1-year post-partum and for immunogenicity, including antibodies in breast milk, until 6 months post-partum. Recruitment was stopped at 51 participants due to rapidity of roll-out of COVID-19 vaccines recommended during pregnancy. Ad26.COV2.S was well-tolerated regardless of previous COVID-19 vaccination history. All pregnancies resulted in a live infant, four were preterm. One serious adverse event of placental insufficiency Day-36 post-vaccination was considered vaccine-related by the investigator. One infant died due to complications associated with an unrelated ventricular septal defect. Ad26.COV2.S induced robust immune responses in women with different COVID-19 vaccination histories. Spike-binding antibody (SAbs) and virus neutralizing antibody (NAbs) titers at delivery tended to be higher in mothers vaccinated during trimester three. Maternal serum and cord blood were strongly correlated. 100% of infants had detectable SAbs at aged 6 months, and 70.6% had detectable NAbs, including 68.2% born to initially vaccine-naïve mothers. Maternal vaccination with an adenovirus-vector vaccine was well-tolerated and immunogenic in mothers and infants. These data could support the adoption of heterologous booster regimens during pregnancy and future adenovirus-vector vaccine development.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2538340"},"PeriodicalIF":3.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12355676/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144849444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Willingness to pay for herpes zoster vaccination in urban China.","authors":"Yanran Wang, Ming Wang, Yiqi Xia, Dawei Zhu, Zhenyu Shi, Ping He","doi":"10.1080/21645515.2025.2559510","DOIUrl":"10.1080/21645515.2025.2559510","url":null,"abstract":"<p><p>Herpes zoster imposes a substantial disease burden in China. Despite vaccination being critical for burden mitigation, willingness-to-pay (WTP) for herpes zoster vaccines among urban residents remains understudied, with a lack of national-level evidence on its determinants. A national-wide survey was conducted among 2,864 urban residents aged ≥25 years across nine provinces and nine cities in China. Using the contingent valuation method (CVM), three elicitation approaches - payment scales, bidding, and open-ended questions - were employed to assess respondents' willingness-to-pay (WTP) for herpes zoster vaccination. Univariate statistical analyses were then performed to explore the associations between socioeconomic characteristics and WTP. Median WTP varied by methods (payment cards: CNY 300, bidding: CNY 500, open-ended: CNY 300). Across these methods, 36.09%, 29.06%, and 23.64% of participants, respectively, were unwilling to pay (including those rejecting free vaccination). For higher thresholds, 2.36% and 9.96% reported WTP ≥ 2,000 CNY via the payment scale and bidding methods, while 2.09% indicated WTP ≥ 2,000 CNY through the open-ended method. Age was negatively associated with WTP, and respondents from moderately developed regions had the highest WTP. Education and annual household income showed positive associations with WTP. Additionally, unemployment, chronic disease, divorced or widowed residents, and below-average self-reported health correlated with lower WTP. While respondents with public or commercial insurance had highest WTP. In conclusion, individual WTP for herpes zoster vaccine is substantially influenced by socioeconomic characteristics, which are inherently linked to income. This highlights the need for income-sensitive policies, including affordable pricing and targeted health education for vulnerable groups.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2559510"},"PeriodicalIF":3.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12445450/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145070913","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of multifunctional T-cell peptide epitopes for the development of DNA vaccines against dengue virus.","authors":"Ningze Sun, Zhiwei Su, Chenghong Yin, Xiaoyan Zheng","doi":"10.1080/21645515.2025.2557097","DOIUrl":"10.1080/21645515.2025.2557097","url":null,"abstract":"<p><p>Dengue virus (DENV) is an important arthropod-borne virus that poses a global health threat, with half of the world's population at risk of infection. Currently, there is a lack of safe and effective vaccines for its prevention. Antibody-dependent enhancement (ADE) occurs when cross-reactive antibodies fail to neutralize heterologous DENV serotypes effectively, facilitating viral entry into Fc receptor-bearing cells and leading to more severe disease. It is reported that multifunctional T cells are closely related to the protective effects of the vaccine. We selected 25 peptide candidates based on predictions from the IEDB database and relevant literature. These peptides were validated to stimulate the production of multifunctional T cells. The DNA sequences of the corresponding peptides were cloned into the pVAX1 vector, and monovalent DNA vaccines for DENV 1-4 were constructed. <i>We analyzed cellular immunity, symptom scores, body weight changes, and survival rates after DENV challenge with the identical immunizing strain</i>.Our studies confirmed that DNA vaccines can protect mice against DENV challenge. Compared with control groups, mice immunized with our DNA vaccines demonstrated better immune protection after being challenged with the corresponding strain of DENV. Our studies provide a basis for the development of new DENV tetravalent vaccines.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2557097"},"PeriodicalIF":3.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12427499/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145031023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In vivo CAR-T cell therapy: New breakthroughs for cell-based tumor immunotherapy.","authors":"Yifan Huang, Rong Cao, Siyang Wang, Xinfeng Chen, Yu Ping, Yi Zhang","doi":"10.1080/21645515.2025.2558403","DOIUrl":"10.1080/21645515.2025.2558403","url":null,"abstract":"<p><p>Chimeric antigen receptor (CAR)-T cell immunotherapy represents an evolutionary advance in the treatment of cancer, yet it faces challenges such as manufacturing complexity, high cost, and time-consuming process. In recent years, the strategy of in vivo CAR-T cell therapy is emerging as a promising approach to improve anti-tumor effectiveness and safety. Briefly, T cells are genetically modified to express CAR protein directly in the body by delivery of vectors. With the continuous optimization of gene delivery systems, gene editing technologies and CAR structures, advancements in in vivo CAR-T therapies have notably enhanced safety, effectiveness, and application in clinical settings. Here, we review the key platforms of in vivo gene delivery and the progress of in vivo CAR-T cell therapy for cancers. We discuss the challenges of in vivo CAR-T cell therapy, such as safety issues of gene delivery, the persistence and function of CAR-T cell, and the immunosuppressive microenvironment in solid tumors.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2558403"},"PeriodicalIF":3.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12427527/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145034394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High coverage with delayed doses: Cross-sectional study of parental acceptance and uptake of varicella vaccination in children aged 4-12 years in Chaoyang District, Beijing.","authors":"Yang Cao, Xinyu Li, Ziwei Zhao, Zhen Li, Fang Liu, Pu Liu, Jianxin Ma, Qian Shi, Nan Zhang, Bin Jia","doi":"10.1080/21645515.2025.2558271","DOIUrl":"10.1080/21645515.2025.2558271","url":null,"abstract":"<p><p>Regional disparities exist in China's varicella vaccination policies, with Beijing's voluntary two-dose program requiring self-payment having been implemented for more than a decade. In this study, we investigated parental acceptance and vaccination patterns among 2,189 children aged 4-12 years in Beijing's Chaoyang District, where policy integration is under consideration. The results revealed high baseline vaccination willingness (81.8%), potentially increasing to 86.3% with inclusion of an immunization program. Key determinants extended beyond demographic factors and disease knowledge to include parental satisfaction with immunization services and utilization of parenting apps. Current coverage rates were 74.5% for the first dose (VarV1) versus 53.2% for the second dose (VarV2), indicating significant second-dose attrition. Primary barriers to vaccination included limited awareness of the option to vaccinate, safety concerns, and perceptions that a single dose offers sufficient protection. Notably, 58.8% of children received VarV1 later than the recommended schedule, partly due to vaccination scheduling. School-based verification requirements emerged as a critical driver of compliance. Our study provides actionable insights for immunization policy optimization. We advocate targeted communication strategies via new media platforms, such as parenting apps, to address knowledge gaps, emphasize two-dose protocols, and boost vaccine confidence. This approach fosters a cycle of tool usage, knowledge acquisition, and timely vaccination, leveraging the demonstrated synergy between app usage and vaccine knowledge in enhancing adherence.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2558271"},"PeriodicalIF":3.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12439547/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145066104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Human vaccines and immunotherapeutics: News September 2025.","authors":"Ronald Ellis, Adam Weiss","doi":"10.1080/21645515.2025.2571369","DOIUrl":"10.1080/21645515.2025.2571369","url":null,"abstract":"","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2571369"},"PeriodicalIF":3.5,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12505499/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145240198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Visual analysis of the research frontiers, hotspots and development trends of immunization programs for women and children.","authors":"Jiachen Zhang, Yani Zhang, Litao Zhang, Jiaxing Wang, Xinheng Qu, Mu Li, Ruochen Zhang, Bo Zhang, Yuqing Zhang, Jianping Zhou","doi":"10.1080/21645515.2024.2442508","DOIUrl":"10.1080/21645515.2024.2442508","url":null,"abstract":"<p><p>The objective of this study is to gain insight into the current research frontiers, hotspots, and development trends in the field of immunization programs for women and children, and to provide scientific guidance and reference for follow-up research. Based on all the original research papers related to the research on immunization programs for women and children in the Web of Science Core Collection (WoSCC) database, bibliometric studies and visual analysis were carried out to explore the research frontiers, hotspots and development trends, and to analyze the risk factors affecting the vaccination coverage of immunization programs for women and children. Eight hundred forty-three papers obtained from 1,552 institutions in 96 countries/regions from January 1950 to August 2024, coauthored by 4,343 authors. With the largest number of papers published in the United States (408), Centers for Disease Control & Prevention - USA (169), Stokley S (15), and Pediatrics (143). The research frontiers of this discipline area mainly involve risk factors affecting the vaccination coverage of immunization programs for women and children, epidemiological surveillance, intervention research, changes in medical burden, adverse reactions, and vaccine development. Research hotspots mainly include measles, vaccine hesitancy, human papillomavirus, coverage, and pregnant women. The findings of the study informed policymakers, public health experts and researchers about the potential for modifying and improving policy systems and interventions related to the immunization programs for women and children. This had important implications for digital transformation and innovative research in health care providers' clinical practice for the immunization programs for women and children.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2442508"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11730636/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142957525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Human papillomavirus vaccination at age 9 or 10 years to increase coverage - a narrative review of the literature, United States 2014-2024.","authors":"Sarah K Brewer, Ruth Stefanos, Neil C Murthy, Amimah F Asif, Shannon Stokley, Lauri E Markowitz","doi":"10.1080/21645515.2025.2480870","DOIUrl":"https://doi.org/10.1080/21645515.2025.2480870","url":null,"abstract":"<p><p>The Advisory Committee on Immunization Practices recommends routine human papillomavirus (HPV) vaccination at 11-12 years; the series can begin at age 9. U.S. HPV vaccination coverage is lower than other adolescent vaccinations. One proposed strategy to increase coverage is initiation at 9-10 years. We systematically reviewed studies addressing vaccination at age 9 to identify and evaluate evidence regarding potential programmatic advantages. Among 30 publications from 2014 to 2024 there were retrospective cohort studies (<i>N</i> = 11), intervention studies with a component focused on vaccination at 9-10 (<i>N</i> = 12), and studies of feasibility or acceptability by providers or caregivers (<i>N</i> = 7). While retrospective analyses found earlier initiation associated with completion, limitations in methodology preclude a cause-and-effect interpretation. Impact of age 9 vaccination is difficult to isolate in intervention studies that had multiple components. While initiating vaccination at age 9 is feasible, questions remain regarding the benefit of this approach to increase coverage.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2480870"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12005419/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144056645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Young men with intellectual disabilities' perceptions of HPV and HPV vaccine: A qualitative study on how to communicate HPV vaccine information.","authors":"Elaine Carnegie, Carol Gray-Brunton, Catriona Kennedy, Janette Pow, Diane Willis, Anne Whittaker","doi":"10.1080/21645515.2025.2491857","DOIUrl":"https://doi.org/10.1080/21645515.2025.2491857","url":null,"abstract":"<p><p>The success of vaccination programs relies on acceptance of recommended vaccines by communities and individuals. There is a paucity of evidence regarding how young men with intellectual disabilities actively produce or receive inclusive and accessible HPV information. As part of a larger qualitative study, we explored how young men with mild-moderate intellectual disabilities contend with information on HPV and how they negotiated safer sex prior to the introduction of the Scottish schools-based gender-neutral HPV vaccination program in 2019. Objectives included identifying strategies for reaching young men with intellectual disabilities; identifying modes of communication that enable young men with intellectual disabilities to discuss HPV; exploring knowledge, awareness, relevance, and participant experiences of HPV vaccination; perceived barriers and facilitators toward vaccination behavior; perceptions of publicly available HPV information and formats. Working with institutions of further education to identify participants, 18 young men chose to participate. Three focus group discussions using activity-oriented questions were conducted. Regardless of ability, a series of activities enabled them to explore questions about their knowledge of HPV and any experience of the vaccination program. Communication aids included familiar objects and symbols from daily life breaking down barriers and power inequities. Data were analyzed drawing on critical discourse analysis. Designed and tailored communication interventions were effective in reaching this population group. Adopting a participatory activity-oriented approach and spending significant time looking at pictures and artifacts enabled young men with mild-moderate intellectual disabilities to discuss behavioral risks and consequences of HPV and to identify design factors for accessible health information.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2491857"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12026243/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144056660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}